Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Human Growth Hormone Market in the US 2015-2019

Published: Mar-2015 | Format: PDF | Technavio | Number of pages: 84 | Code: MRS - 7276

 

Human growth hormone, also known as somatotropin, is a peptide with 191 amino acids and 2 sulfhydryl bridges. It is produced by the anterior pituitary, and it is required to attain normal size for children and adolescents. It also has major effects on lipid and carbohydrate metabolism of an individual. The effects of human growth hormone are mainly mediated by IGF-1 and IGF-2. There are two forms of recombinant human growth hormone approved in the market: Somatropin and Somatrem. Somatropin has 191 amino acids and Somatrem contains 192 amino acids. Growth hormone deficiency can occur either due to a damage to the pituitary or the hypothalamus gland, or can also be acquired genetically. Some of the signs of growth hormone deficiency are adiposity, short stature, and hypoglycemia.

 

The analysts forecast the Human Growth Hormone market in the US to grow at a CAGR of 3.86 percent over the period 2014-2019.

 

Covered in this Report

 

This report covers the present scenario and the growth prospects of the Human Growth Hormone market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the various human growth hormone drugs available in the US for the treatment of growth hormone deficiency.

 

The report, the Human Growth Hormone Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Human Growth Hormone market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

 

Key Vendors

 

F. Hoffmann-La Roche
Merck Serono
Novo Nordisk
Pfizer

 

Other Prominent Vendors

 

Eli Lilly
Teva Pharmaceutical
Novartis
Ipsen

 

Market Driver

 

Demand for Human Growth Hormone
For a full, detailed list, view our report

 

Market Challenge

 

High Cost of Therapy
For a full, detailed list, view our report

 

Market Trend

 

Growing Focus on Needle-free Drug Delivery Devices
For a full, detailed list, view our report

 

Key Questions Answered in this Report

 

What will the market size be in 2019 and what will the growth rate be
What are the key market trends
What is driving this market
What are the challenges to market growth
Who are the key vendors in this market space
What are the market opportunities and threats faced by the key vendors
What are the strengths and weaknesses of the key vendors

Table of Contents

 

01. Executive Summary

 

02. List of Abbreviations

 

03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings

 

04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

 

05. Human Growth Hormone: An Overview
05.1 About Human Growth Hormone
05.2 Pharmacological Action of Human Growth Hormone
05.3 Therapeutic Uses of Human Growth Hormone: US FDA
05.4 Growth Hormone Deficiency
05.4.1 Childhood-onset growth hormone deficiency
05.4.2 Adult-onset growth hormone deficiency

 

06. Introduction

 

07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

 

08. Buying Criteria

 

09. Market Growth Drivers

 

10. Drivers and their Impact

 

11. Market Challenges

 

12. Impact of Drivers and Challenges

 

13. Market Trends

 

14. Trends and their Impact

 

15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Market Share Analysis 2014
15.2.1 Merck Serono
15.2.2 Pfizer
15.2.3 Novo Nordisk
15.2.4 F. Hoffmann-La Roche
15.3 Other Prominent Vendors

 

16. Key Vendor Analysis
16.1 F. Hoffmann-La Roche Ltd.
16.1.1 Key Facts
16.1.2 Business Overview
16.1.3 Business Segmentation
16.1.4 Business Segmentation by Revenue 2012 and 2013
16.1.5 Sales by Geography
16.1.6 Business Strategy
16.1.7 Key Information
16.1.8 SWOT Analysis
16.2 Merck Serono
16.2.1 Key Facts
16.2.2 Business Overview
16.2.3 Geographical Segmentation by Revenue 2013
16.2.4 Business Strategy
16.2.5 Recent Developments
16.2.6 SWOT Analysis
16.3 Novo Nordisk A/S
16.3.1 Key Facts
16.3.2 Business Overview
16.3.3 Business Segmentation by Revenue 2013
16.3.4 Business Segmentation by Revenue 2012 and 2013
16.3.5 Sales by Geography
16.3.6 Business Strategy
16.3.7 Key Information
16.3.8 SWOT Analysis
16.4 Pfizer
16.4.1 Key Facts
16.4.2 Business Overview
16.4.3 Business Segmentation by Revenue 2013
16.4.4 Business Segmentation by Revenue 2012 and 2013
16.4.5 Geographical Segmentation by Revenue
16.4.6 Business Strategy
16.4.7 Key Developments
16.4.8 SWOT Analysis

 

17. Other Reports in this Series

 

List of Exhibits:

 

Exhibit 1: Market Research Methodology
Exhibit 2: Structure of Human Growth Hormone
Exhibit 3: Clinical Uses of Recombinant Human Growth Hormone
Exhibit 4: Regulation of Human Growth Hormone and Its Effects
Exhibit 5: Types of Growth Hormone Deficiency
Exhibit 6: Human Growth Hormone Market in US 2014-2019 (US$ million)
Exhibit 7: NovoFine Needle
Exhibit 8: NordiPenMate
Exhibit 9: Human Growth Hormone Market in US Market Share Analysis 2014
Exhibit 10: Market Share Comparison of Major Drugs 2014 (US$ million)
Exhibit 11: YoY Global Sales and Growth Rate of Saizen 2011-2013 (US$ million)
Exhibit 12: Parts of Click.easy
Exhibit 13: Easypod Drug Delivery Device
Exhibit 14: Parts of Cool.click 2
Exhibit 15: One.click Drug Delivery Device
Exhibit 16: Serojet Drug Delivery Device
Exhibit 17: Genotropin Miniquick
Exhibit 18: Parts of Genotropin Miniquick
Exhibit 19: Genotropin Mixer
Exhibit 20: Parts of Genotropin Mixer
Exhibit 21: Genotropin Pen
Exhibit 22: Parts of Genotropin Pen
Exhibit 23: YoY Global Sales and Growth Rate of Genotropin 2011-2013 (US$ million)
Exhibit 24: YoY Global Sales and Growth Rate of Norditropin 2012-2014 (US$ million)
Exhibit 25: Dosage Strengths of FlexPro
Exhibit 26: Dosage Strengths of NordiFlex
Exhibit 27: Dosage Strengths of Norditropin NordiLet
Exhibit 28: Dosage Strengths of Nordipen
Exhibit 29: Parts of Nordipen
Exhibit 30: YoY Global Sales and Growth Rate of Nutropin 2010-2013 (US$ million)
Exhibit 31: Comparison of the Global and US Sales of Nutropin 2012-2013 (US$ million)
Exhibit 32: Parts of Nutropin AQ NuSpin
Exhibit 33: Nutropin AQ NuSpin 20
Exhibit 34: Nutropin AQ NuSpin 10
Exhibit 35: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 36: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 37: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 38: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 39: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 40: Novo Nordisk A/S: Business Segmentation by Revenue 2013
Exhibit 41: Novo Nordisk A/S: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 42: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 43: Pfizer: Business Segmentation by Revenue 2013
Exhibit 44: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 45: Pfizer: Geographical Segmentation by Revenue 2013

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)2500 View Pricing